Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill, et al.
Metabolism (2024) Vol. 154, pp. 155835-155835
Open Access | Times Cited: 79
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Yehuda Handelsman, John E. Anderson, George L. Bakris, et al.
Metabolism (2024) Vol. 159, pp. 155931-155931
Open Access | Times Cited: 21
The association between the dietary index for gut microbiota and metabolic dysfunction-associated fatty liver disease: a cross-sectional study
Yangyang Zheng, Jinhui Hou, Shiqi Guo, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 3
Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus
Mengmeng Hu, Jingyu Yang, Beibei Gao, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group
Andrej Janež, Emir Muzurović, Paweł Bogdański, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 9, pp. 1865-1892
Open Access | Times Cited: 13
Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management
Stergios A. Pοlyzos, Christos S. Mantzoros
Metabolism (2024) Vol. 157, pp. 155936-155936
Closed Access | Times Cited: 10
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 9
Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis
Rutao Lin, Qinmei Sun, Xin Xin, et al.
Metabolism (2024) Vol. 161, pp. 156043-156043
Closed Access | Times Cited: 7
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis
Maria‐Ioanna Stefanou, Lina Palaiodimou, Aikaterini Theodorou, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 6
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance
Angelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Metabolism (2024), pp. 156080-156080
Open Access | Times Cited: 5
FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD)
Stewart G. Albert, Emily M. Wood
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 7, pp. 108777-108777
Closed Access | Times Cited: 4
Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
Emidio Scarpellini, Marialaura Scarcella, Jan Tack, et al.
Antioxidants (2024) Vol. 13, Iss. 11, pp. 1386-1386
Open Access | Times Cited: 4
Hinokitiol ameliorates MASH in mice by therapeutic targeting of hepatic Nrf2 and inhibiting hepatocyte ferroptosis
Xunzhe Yin, Zuojia Liu, Chang Li, et al.
Phytomedicine (2025) Vol. 139, pp. 156472-156472
Closed Access
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?
Konstantinos Arvanitakis, Theocharis Koufakis, Εvangelos Cholongitas, et al.
Pharmacology & Therapeutics (2025), pp. 108811-108811
Open Access
Analyzing MASLD interventional clinical trial registration based on the ClinicalTrials.gov database
Hui Du, Jihan Huang, Youhua Wang, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access
Mesenchymal stem cell-derived small extracellular vesicles reduced hepatic lipid accumulation in MASLD by suppressing mitochondrial fission
Yifei Chen, Fuji Yang, Yanjin Wang, et al.
Stem Cell Research & Therapy (2025) Vol. 16, Iss. 1
Open Access
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Weixin Wang, Xin Gao, Wei Niu, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 9, pp. 4077-4077
Open Access
Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue
Alberto Savino, Alessandro Loglio, Flavia Neri, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 13, pp. 3871-3871
Open Access | Times Cited: 3
Is MASLD a real culprit for all-cause mortality? A meta-analysis and preliminary pathophysiology exploration in the real world
Zheng Li, Zhiping Li, Dan Cao, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 2
GDF-15 improves the predictive capacity of Steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignancies
Michail Kokkorakis, Pytrik Folkertsma, José Castela Forte, et al.
Metabolism (2024), pp. 156047-156047
Closed Access | Times Cited: 2
Is MetALD an independent risk factor of all-cause mortality? A meta-analysis of 164,694 individuals from the real world
Zheng Li, Yali Shen, Zhiping Li, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 2
Liver Fibrosis and Atherosclerosis, a Consequence of Metabolic Dysfunction—Do They Share a Similar Pathophysiological Background?
Emir Muzurović, Marija Maćešić, Sreten Kavarić
Angiology (2024)
Open Access | Times Cited: 1
Epicardial and liver fat implications in albuminuria: a retrospective study
Carolina M. Perdomo, Nerea Martín‐Calvo, Ana Ezponda, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Monitoring the liver as a part of the cardio-renal-metabolic continuum – What is cooking and burning with non-invasive tests and treatment options?
Špela Volčanšek, Andrej Janež, Manfredi Rizzo, et al.
Journal of Diabetes and its Complications (2024), pp. 108875-108875
Closed Access | Times Cited: 1
Hope on the Horizon: Promising Therapies for Steatotic Liver Disease
Amirhossein Sahebkar, Ali H. Eid
Pharmacological Reviews (2024) Vol. 76, Iss. 4, pp. 561-563
Closed Access
Page 1 - Next Page

Scroll to top